Share Name Share Symbol Market Type Share ISIN Share Description
Hemogenyx Pharmaceuticals Plc LSE:HEMO London Ordinary Share GB00BYX3WZ24 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  0.25 2.5% 10.25 2,611,738 16:21:04
Bid Price Offer Price High Price Low Price Open Price
10.00 10.50 10.75 9.90 10.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -1.12 44
Last Trade Time Trade Type Trade Size Trade Price Currency
16:29:18 O 73,978 10.235 GBX

Hemogenyx Pharmaceuticals (HEMO) Latest News

More Hemogenyx Pharmaceuticals News
Hemogenyx Pharmaceuticals Takeover Rumours

Hemogenyx Pharmaceuticals (HEMO) Discussions and Chat

Hemogenyx Pharmaceuticals Forums and Chat

Date Time Title Posts
26/9/202014:18HEMO ANTIBODIES Viruses, Disease X Pathogens Bloods stem cells1,003
22/9/202015:43Hemogenyx Blockbuster IP licencing to Big Pharma70
21/9/202011:35HEMO INVESTORS ONLY476

Add a New Thread

Hemogenyx Pharmaceuticals (HEMO) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Hemogenyx Pharmaceuticals trades in real-time

Hemogenyx Pharmaceuticals (HEMO) Top Chat Posts

Hemogenyx Pharmaceuticals Daily Update: Hemogenyx Pharmaceuticals Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HEMO. The last closing price for Hemogenyx Pharmaceuticals was 10p.
Hemogenyx Pharmaceuticals Plc has a 4 week average price of 9.25p and a 12 week average price of 5.90p.
The 1 year high share price is 15.38p while the 1 year low share price is currently 1.05p.
There are currently 433,636,255 shares in issue and the average daily traded volume is 3,123,135 shares. The market capitalisation of Hemogenyx Pharmaceuticals Plc is £44,447,716.14.
purple11: The Hemogenyx share price is up 1,400% since April. Here’s what you need to know Alan Oscroft | Wednesday, 26th August, 2020 | More on: HEMO Coronavirus 2019-nCoV Blood Samples Medical ConceptImage source: Getty Images Since the Covid-19 pandemic hit, investors have been searching for pharmaceuticals and biotechnology stocks that could hit the big time. Enter Hemogenyx Pharmaceuticals (LSE: HEMO). For the first few months of 2020, this tiny biotech firm looked like the typical penny stock. It’s been showing no profits, and the Hemogenyx share price was wobbling around a penny or two. 5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit! According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air… And if you click here we’ll show you something that could be key to unlocking 5G’s full potential... Hemogenyx has been researching blood cancers and autoimmune diseases. Then, in April, the firm announced the start of its Covid-19 project. And the Hemogenyx share price took off. Before I look at the investment case, what’s the technology all about? Hemogenyx uses humanised mice or, in technical terms, Advanced peripheral blood Hematopoietic Chimera (ApbHC). They “were developed to model blood and autoimmune diseases and to test treatments.” Covid-19 research These mice were already being used to research antibodies for use as antiviral therapies. So the leap to Covid-19 seems an obvious one. In the company’s words: “As part of its studies, Hemogenyx will transplant cells from blood samples from patients who are either recovering or have already recovered from Covid-19 into its ApbHC humanized mice. The process will allow the Company’s scientists to recreate a set of anti-SARS-CoV-2 virus antibodies which could be used for the treatment of Covid-19.“ Some people react severely to Covid-19 infection, while some experience mild or even no symptoms. And the first stage is to try to find out why. Hemogenyx share price flying In the week following the announcement, the Hemogenyx share price soared from 1.83p to 10.8p. That was a quick six-fold increase, and a massive gain since April’s low of 0.95p. Since then, the shares remained around that level until very recently. On 20 August, the price started to pick up again. And we’ve only had news of a research agreement unrelated to the coronavirus. As I’m writing, I’m looking at a further 24% rise on the day so far. I’m having to change my headline as the hours progress. Hemogenyx has certainly caught the attention of investors, but I’m very cautious. Some experienced growth investors will see genuine potential here for long-term gains. They’ll understand the attached risks and will be prepared to take them on. After all, just one multi-bagger in every five or six punts can be enough to make some decent money. But there must also be some ‘get rich quick’ investors chasing the Hemogenyx share price upwards too. And that’s rarely a strategy for success. More gains to come? Right now, I have no way of evaluating the chances of Hemogenyx making the big breakthrough. Humanised mice are nothing new in themselves. But I don’t have the expertise to know whether the Hemogenyx ones are especially promising. And there must be a possibility that an effective vaccine could render this research largely obsolete. And then there’s the current profitless nature of the company, which makes it impossible for me to put a value on it. The share price might be up at 14.5p now (or even higher by the time you read this — or maybe it’s already crashed). But to me it still has all the characteristics of a penny stock, and the Hemogenyx share price looks like a pure gamble.
justhereforhemo: RE IdontflyKathyy This is the email I have sent to support at advfn along with Hemogenyx directly. I have also included copies of her defamatory and what I consider illegal posts which defame character and attempt to manipulate the market. As a shareholder and therefore a victim should this damage the reputation of hemogenyx and depress its share price causing me a material loss I have also logged a non-emergency report with the Police Service in my local jurisdiction which is not England so it may take a while for them to take any sort of action here. However please note I am serious about putting a stop to this sort of behaviour. Please remove posts accusing Dr Vlad of being a fraud or criminal immediately. Please remove posts accusing Hemogenyx of being fraudulent or fake in any way. If you wish to attempt to lower the Share Price use legal methods. Please note the posts on this forum are crossing the line into market manipulation, deformation of character and illegality. Making clearly false statements with the intent to depress share price. I have notified Dr Sandler and posted a reply on the thread. Please deal with this immediately, as you have been made aware you are now required by law to take action. Many thanks
mms98: Tully, if you right clicked and opened the post on a new link it works. Here is a copy. Hemogenyx Pharmaceuticals (LON: HEMO) up over 260% as it searches for COVID antibodies Companies that can as good as guarantee investor interest in these crazy times are, besides those producing toilet paper and sanitizers, companies involved in some sort of solution to the coronavirus pandemic. London-listed biopharma firm Hemogenyx Pharmaceuticals (LON: HEMO) is no exception. Still time to enter The Armchair Trader’s stock picking competition and donate to the NHS The relatively small biotech company has been developing treatments for blood cancers and autoimmune diseases over the last seven years but came to investors’ attention last week when it announced that it its looking to discover antibodies that can fight Covid 19. Hemogenyx Pharmaceuticals and humanised mice Hemogenyx Pharmaceuticals is using its proprietary ‘humanised mice’ which have been developed for previous research to focus on coronavirus antibodies. While some people infected by Covid 19 shake the disease off with almost no symptoms others fall severely ill. Hemogenyx’s team is now running a pilot project to figure out why that is the case, and to substantiate it with data. “We are using our new generation of humanised mice to discover human neutralising antibodies that were developed by convalescent patients, patients that fell ill and developed antibodies against this virus,” Hemogenyx chief executive and co-founder Vladislav Sandler told The Armchair Trader today. “Once discovereed, the company plans to clone the antibodies and develop them into a drug.” The time frame for this? As soon as possible, says Sandler. The Hemogenyx share price rocketed 260% in the space of a week, rising from around 2 pence last Friday to a high of 15.1 this week. Given its small cap nature – is has a market capitalization of £36m – investor interest generated so much price movement this week that there have been two price monitoring extensions on the share per day over the last few days. Research facility in coronavirus central The firm runs a state of the art research facility in what is now coronavirus central: New York City, and has not stopped work throughout the outbreak of the pandemic. Even without its COVID 19-related work, Hemogenyx Pharmaceuticals interests us because of its expertise in stem cell-related solutions for severe blood diseases and its focus on pre-clinical stage medicines and treatments for autoimmune diseases. Autoimmune conditions such as lupus, type 1 diabetes and multiple sclerosis are unfortunately on the rise. There is no good explanation as to why, but this type of disease is about three times more common now than only a few decades ago, and yet is fairly costly to treat because it requires life-long medication. Hemogenyx Pharmaceuticals already has good links with the rest of the biotech industry and is collaborating with partners like Johnson and Johnson, the University of Oxford and LakeParma on various projects. This will position it as an interesting investment not only in the short term but also once the corona dust has settled. Regards MMS98 Credit
tidy 2: Hemogenyx (HEMO): A Covid-19 Cure Instead Of Just A Vaccine? #HEMOA small laboratory in Brooklyn may at first glance appear to be an unlikely location for potentially transformational breakthroughs in blood diseases, or these days, Covid-19. However, such an assumption may not be counting on the inventive scientific brain of Dr Vladislav Sandler. CEO of Hemogenyx.hemoIn fact, he runs a tight ship, both in terms of cost and the number of personnel. That Dr Sandler's company has been punching above its weight in recent years is due not only to his direct efforts. Backed by a strong advisory team, the £23m market cap group has access to the best research facilities and resources courtesy of its big pharma collaborations.Of course, so much currently in the biotech / pharma space is centred around hopes of Covid-19 being conquered. The logical approach here is to employ existing work on viruses and see whether it can be applied to this new strain? In this respect it is interesting note that previous research with measles appears to be useful. Indeed, rather in the way that Cowpox led to the demise of Smallpox, it may be that Measles helps in the fight against Covid-19. But this trail gets better.Whereas Edward Jenner's achievement was a vaccine against Smallpox, we have the possibility of Hemogenyx being able to develop a cure for Covid-19, something not yet on the map in terms of the pharma Gold Rush in this space. This will no doubt cheer the anti-vaxxer conspiracy theorists, but lead us to a logical conclusion to the whole coronavirus saga: a cure for Virus X. The implication being that the research at Hemogenyx could offer a cure not only for the current pandemic, but develop one for future virus strains yet to be seen.As well as this there is the possibilty of being able to drill down into some of the characteristics of Covid-19, and one of its great mysteries: why some of us are symptomless and others are in receipt of a potentially deadly pathogen? Ongoing autoimmune disease research at Hemogenyx could provide answers, and show us that rather than the company being opportunistic in the face of the current pandemic, there is actually a genuine humanitarian angle to the work in progress over and above the science.But for those concerned that somehow Dr Sandler and his team are veering away from the day job, blood cancer treatments and therapies are now being addressed on not one but two fronts: CDX antibodies and CAR-T therapies. Clearly, having two treatment routes for the same ailment is better both for the patient and the commercial opportunities down the line at Hemogenyx, something the recent share price spike will have alerted many pharma sector fans to in recent weeks. This is also the backbone for the group should the current sector focus on Covid-19 fade.
tullynessle: Noting reports in the media that: i. future immunity is not assured for those who have contracted Covid-19. and ii. there is a risk that the current Covid-19 virus may mutate iii. there does not appear to be a Covid-19 vaccine or drug to manage its symptoms at this time, or in the near future. IMO, it is imperative that over the short and longer term, the technology contemplated by Hemogenyx, and described in the paragraph at "Extract" below, is successful, (not only as applicable to Covid-19 but to potentially, "a host of viral pathogens" It should be noted that it appears Hemogenyx's patented "ApbHC humanized mice" will be an integral component of HEMOs study. I own shares in HEMO / DYOR Extract: "In addition, the study will aim to demonstrate how Hemogenyx's technology can be deployed rapidly in emergencies in order to discover human neutralizing antibodies against a host of viral pathogens, including what infectious disease experts in the bioprotection and biodefense sectors call "Disease X", meaning as-yet unknown viruses that may represent a similar or greater threat than the one presented by COVID-19." Hemogenys - RNS Hemogenyx Pharmaceuticals PLC COVID-19 Project Initiated 22/04/2020 Hemogenyx to use its advanced humanized mice to develop potential treatments for COVID-19. Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is deploying its groundbreaking research and technologies to develop potential treatments for COVID-19. News Release continues.....
bunz3: ncyt share price moving back up buyers loading there again like how hemo share price going today
tullynessle: In two RNSs issued by Hemogenyx, (24Jun19 & 30Sep19), the Company indicates that the directors believe that ApbHC could be used in Biodefense Applications - see below. It would be useful to shareholders if said Directors provided some colour to that statement, basically: i. What is the Market - describe? ii. What is the Hemogenyx technology that can be launched in that Market? iii. What is the size of the Market - range of potential Clients / $Value? iv. How does the Hemogenoyx technology work? v. Who else competes in the same Market? vi. Is Hemogenyx ready to launch into the contemplated Market - is its technology ready? vii. Does the Hemogenyx contemplated technology have a role in neutralising the Coronovirus threat? viii.Why is there an absence of any detail concerning the potential use of Hemogenyx technology for a biodefense application? Anyone in contact with Dr Sandler or other contact within the Company. 24 June 2019 Hemogenyx Pharmaceuticals plc Extract: "The Directors also believe that the ApbHC could potentially be used as a tool for the rapid development and/or isolation of human antibodies against unknown human-specific pathogens (biodefense applications)." ======================= Hemogenyx Pharmaceuticals PLC Half-year Report 30/09/2019 7:01am " The Directors also believe that the ApbHC could potentially be used as a tool for the rapid development and/or isolation of human antibodies against unknown human-specific pathogens (biodefence applications)."
marie1980: Fair point about ramping, Dave. Good information. About hemo share price, I think during spike there will be huge volume as history suggests and that’s the time we should get out. So need to keep an eye on this share daily. But now as since I’ve decided to stick with 1-2 years of time, I will stick with it and buy should she test lower. One thing is sure and I think everyone should agree that if in 2020 if no news for IND or phase 1 then 😢
bc4: Let me put it in to perspective on the 10th of June HEMO share price was about 2.5p it is now 3.15p so take no notice of the muppet
pwhite73: dave4545 - "Killing the market and full time deramper vultures like pwhite clean up" Wrong never shorted a share in my life and PIs generally cannot short AIM and micro-cap stocks only institutions can. What I have learned over the years is do not hold AIM/micro-cap stocks long term. If you do you will pay the price with diluted placings, warrants, options, conversion loans, death spiral financing and eventually suspension and cancellation. You trade these stocks on a daily or weekly basis. I have a particular interest in bio-pharma stocks because these are the ones that can really motor if the markets believe their story. I check the ADVFN 'Toplists' daily to look at the biggest percentage risers and fallers. I normally base my trades around these. Hemo came onto my radar again as it was a big riser for 30/05/2019. I had previously noted that Hemo could never seem to hold onto any gains, that is when I really started taking a look at the company. The cracks and fissures that are in PYC and ERX can be found in Hemo. It doesn't really have anything to re-rate it. True to form Hemo share price has collapsed again. But it will rise again on the next positive RNS and fall again as day traders pile in and out whilst the market professionals short the stock.
Hemogenyx Pharmaceuticals share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Hemogenyx ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200927 23:40:28